Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

HC Wainwright & Co. Downgrades Taro Pharmaceutical Indus to Neutral, Maintains Price Target to $43

Author: Benzinga Newsdesk | January 18, 2024 07:15am
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Taro Pharmaceutical Indus (NYSE:TARO) from Buy to Neutral and maintains the price target from $43 to $43.

Posted In: TARO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist